These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23293111)

  • 1. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
    Oakman C; Francis PA; Crown J; Quinaux E; Buyse M; De Azambuja E; Margeli Vila M; Andersson M; Nordenskjöld B; Jakesz R; Thürlimann B; Gutiérrez J; Harvey V; Punzalan L; Dell'orto P; Larsimont D; Steinberg I; Gelber RD; Piccart-Gebhart M; Viale G; Di Leo A
    Ann Oncol; 2013 May; 24(5):1203-11. PubMed ID: 23293111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
    Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
    J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
    Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
    Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
    Di Leo A; Crown J; Nogaret JM; Duffy K; Bartholomeus S; Dolci S; Rowan S; O'Higgins N; Paesmans M; Larsimont D; Riva A; Piccart MJ
    Ann Oncol; 2000 Feb; 11(2):169-75. PubMed ID: 10761751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
    De Placido S; De Laurentiis M; De Lena M; Lorusso V; Paradiso A; D'Aprile M; Pistillucci G; Farris A; Sarobba MG; Palazzo S; Manzione L; Adamo V; Palmeri S; Ferraù F; Lauria R; Pagliarulo C; Petrella G; Limite G; Costanzo R; Bianco AR;
    Br J Cancer; 2005 Feb; 92(3):467-74. PubMed ID: 15668708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
    Ellis P; Barrett-Lee P; Johnson L; Cameron D; Wardley A; O'Reilly S; Verrill M; Smith I; Yarnold J; Coleman R; Earl H; Canney P; Twelves C; Poole C; Bloomfield D; Hopwood P; Johnston S; Dowsett M; Bartlett JM; Ellis I; Peckitt C; Hall E; Bliss JM; ;
    Lancet; 2009 May; 373(9676):1681-92. PubMed ID: 19447249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
    Swain SM; Jeong JH; Geyer CE; Costantino JP; Pajon ER; Fehrenbacher L; Atkins JN; Polikoff J; Vogel VG; Erban JK; Rastogi P; Livingston RB; Perez EA; Mamounas EP; Land SR; Ganz PA; Wolmark N
    N Engl J Med; 2010 Jun; 362(22):2053-65. PubMed ID: 20519679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
    Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
    Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
    Goldstein LJ; O'Neill A; Sparano JA; Perez EA; Shulman LN; Martino S; Davidson NE
    J Clin Oncol; 2008 Sep; 26(25):4092-9. PubMed ID: 18678836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
    Coudert B; Asselain B; Campone M; Spielmann M; Machiels JP; Pénault-Llorca F; Serin D; Lévy C; Romieu G; Canon JL; Orfeuvre H; Piot G; Petit T; Jerusalem G; Audhuy B; Veyret C; Beauduin M; Eymard JC; Martin AL; Roché H;
    Oncologist; 2012; 17(7):900-9. PubMed ID: 22610153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
    Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
    Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
    Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.